Hepatitis C Diagnosis and Treatment Market Size, Trends and Growth Analysis By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032

Table of Contents

REPORT PROLOGUE

MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS

6.1. Overview

6.2. Liver Function Tests

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Liver Biopsy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Blood Tests

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Antiviral Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Immuno-Modulators

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Liver Transplantation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Hepatitis C Diagnosis and Treatment Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of the Number of Developments in the Global Hepatitis C Diagnosis and Treatment Market

10.7. Key Developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

COMPANY PROFILES

11.1. F. Hoffmann-La Roche Ltd

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Vertex Pharmaceuticals Incorporated

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Gilead Sciences, Inc.

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. AbbVie Inc.

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. GlaxoSmithKline plc

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Novartis Pharmaceuticals Corporation

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Bristol-Myers Squibb Company

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Abbott.

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Beckman Coulter, Inc.

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Siemens Medical Solutions USA, Inc.

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. MedMira Inc.

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. DiaSorin SpA

11.12.1. Company Overview

11.12.2. Product Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Qiagen

11.13.1. Company Overview

11.13.2. Product Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. bioMérieux SA

11.14.1. Company Overview

11.14.2. Product Overview

11.14.3. Financial Overview

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

11.15. Hologic, Inc.

11.15.1. Company Overview

11.15.2. Product Overview

11.15.3. Financial Overview

11.15.4. Key Developments

11.15.5. SWOT Analysis

11.15.6. Key Strategies

11.16. Bio-Rad Laboratories, Inc.

11.16.1. Company Overview

11.16.2. Product Overview

11.16.3. Financial Overview

11.16.4. Key Developments

11.16.5. SWOT Analysis

11.16.6. Key Strategies

11.17. Others

APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 11 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 12 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 14 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET

FIGURE 4 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY DIAGNOSIS, 2020 (%)

FIGURE 5 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 6 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 15 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 16 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 17 VERTEX PHARMACEUTICALS INCORPORATED: KEY FINANCIALS

FIGURE 18 VERTEX PHARMACEUTICALS INCORPORATED: SEGMENTAL REVENUE

FIGURE 19 VERTEX PHARMACEUTICALS INCORPORATED: REGIONAL REVENUE

FIGURE 20 GILEAD SCIENCES, INC.: KEY FINANCIALS

FIGURE 21 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE

FIGURE 22 GILEAD SCIENCES, INC.: REGIONAL REVENUE

FIGURE 23 ABBVIE INC.: KEY FINANCIALS

FIGURE 24 ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 25 ABBVIE INC.: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 NOVARTIS PHARMACEUTICALS CORPORATION: KEY FINANCIALS

FIGURE 30 NOVARTIS PHARMACEUTICALS CORPORATION: SEGMENTAL REVENUE

FIGURE 31 NOVARTIS PHARMACEUTICALS CORPORATION: REGIONAL REVENUE

FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 34 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 35 ABBOTT.: KEY FINANCIALS

FIGURE 36 ABBOTT.: SEGMENTAL REVENUE

FIGURE 37 ABBOTT.: REGIONAL REVENUE

FIGURE 38 BECKMAN COULTER, INC.: KEY FINANCIALS

FIGURE 39 BECKMAN COULTER, INC.: SEGMENTAL REVENUE

FIGURE 40 BECKMAN COULTER, INC.: REGIONAL REVENUE

FIGURE 41 SIEMENS MEDICAL SOLUTIONS USA, INC.: KEY FINANCIALS

FIGURE 42 SIEMENS MEDICAL SOLUTIONS USA, INC.: SEGMENTAL REVENUE

FIGURE 43 SIEMENS MEDICAL SOLUTIONS USA, INC.: REGIONAL REVENUE

FIGURE 44 MEDMIRA INC.: KEY FINANCIALS

FIGURE 45 MEDMIRA INC.: SEGMENTAL REVENUE

FIGURE 46 MEDMIRA INC.: REGIONAL REVENUE

FIGURE 47 DIASORIN S.P.A.: KEY FINANCIALS

FIGURE 48 DIASORIN S.P.A.: SEGMENTAL REVENUE

FIGURE 49 DIASORIN S.P.A.: REGIONAL REVENUE

FIGURE 50 QIAGEN: KEY FINANCIALS

FIGURE 51 QIAGEN: SEGMENTAL REVENUE

FIGURE 52 QIAGEN: REGIONAL REVENUE

FIGURE 53 BIOMÉRIEUX SA: KEY FINANCIALS

FIGURE 54 BIOMÉRIEUX SA: SEGMENTAL REVENUE

FIGURE 55 BIOMÉRIEUX SA: REGIONAL REVENUE

FIGURE 56 HOLOGIC, INC.: KEY FINANCIALS

FIGURE 57 HOLOGIC, INC.: SEGMENTAL REVENUE

FIGURE 58 HOLOGIC, INC.: REGIONAL REVENUE

FIGURE 59 BIO-RAD LABORATORIES, INC.: KEY FINANCIALS

FIGURE 60 BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE

FIGURE 61 BIO-RAD LABORATORIES, INC.: REGIONAL REVENUE